Artes Medical Announces Plan for Nasdaq Listing Compliance and Agenda for Its Annual Meeting

Business Wire, Sept 2, 2008

We encourage you to participate in the Company's Annual Meeting and vote your proxy in accordance with the recommendations of the Company's Board of Directors and management. Thank you again for your continued support of the Company.

Most sincerely,

Christopher J. Reinhard
Executive Chairman of the Board of Directors

Forward-Looking Statements

This press release contains forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management and Board of Directors. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, which include the Company's history of net losses, its ability to timely raise additional funds to support its operations and future product acquisition plans, its ability to manage its operating expenses, its reliance on sales of ArteFill and Elevess, its future receipt of FDA approval to extend the efficacy period of ArteFill beyond six months and eliminate the skin test requirement, and the risk that the Company's revenue projections may prove incorrect because of unexpected difficulty in generating sales and market acceptance of ArteFill and Elevess, readers are cautioned not to place undue reliance on any forward-looking statements included in this letter to stockholders. A more extensive set of risks and uncertainties is set forth in the Company's SEC filings available at www.sec.gov. These forward-looking statements represent beliefs and assumptions only as of the date of this press release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Important Additional Information

On August 29, 2008, the Company filed a preliminary proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the solicitation of proxies for its Annual Meeting. The Company intends to mail a definitive proxy statement (the "Proxy Statement") to its stockholders prior to the Annual Meeting. The Proxy Statement will contain important information about the Company and the Annual Meeting. The Company's stockholders are urged to read the Proxy Statement carefully. Stockholders will be able to obtain copies of the Proxy Statement and other documents filed by the Company with the SEC in connection with the Annual Meeting at the SEC's website at www.sec.gov or at the Investor Relations section of the Company's website at www.artesmedical.com. The Company, its Board of Directors and its management may be deemed participants in the solicitation of proxies from stockholders in connection with the Annual Meeting. Information regarding the stock holdings and other direct or indirect interests of the Company's Board of Directors and management in the proposals to be voted upon at the Annual Meeting are described in the Proxy Statement. The contents of the websites referenced above are not deemed to be incorporated by reference into the Proxy Statement.